Gastrointestinal Stromal Tumor of the Prostate: Staging and Evaluation of Response to Therapy With 18F-FDG PET/CT. (January 2018)

• Record Type: Journal Article
• Authors: Alabed, Yazan Z.
• Is Part Of: Clinical nuclear medicine. Volume 43:Number 1(2018)
• Publication Date: 2018-01
• Subjects: FDG -- PET/CT -- GIST -- EGIST -- imatinib -- prostate; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000001906
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 49-year-old man presented for routine general physical examination was found with an enlarged prostate gland without associated symptoms. Ultrasound followed by computed tomography (CT) of abdomen and pelvis confirmed a markedly enlarged heterogeneous prostate gland. Subsequently, a staging flourine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET/CT) scan revealed intensely FDG-avid mass involving the prostate, which was biopsied as gastrointestinal stromal tumor (GIST). The patient was treated with imatinib and a follow-up PET/CT scan showed complete metabolic response. 18 F-FDG PET/CT scan is useful in staging and follow-up of this very rare extragastrointestinal stromal tumor (EGIST).